News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
News
Business
Micrus Endovascular Corporation Third Quarter Results Feature Revenues Up 92%
February 12, 2007
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
SAN JOSE, Calif.--(BUSINESS WIRE)--Micrus Endovascular Corporation (Nasdaq:MEND) today announced financial results for the three and nine months ended December 31, 2006.
Twitter
LinkedIn
Facebook
Email
Print
Earnings
MORE ON THIS TOPIC
Layoff Tracker
4DMT Thins Early-Stage Workforce, Focuses on Late-Stage Activities
July 3, 2025
·
152 min read
·
BioSpace Editorial Staff
Podcast
CAR T Expands, M&A Ticks Up, Two Psychedelics Read Out, and the Supreme Court Rules on PrEP
July 2, 2025
·
1 min read
·
Heather McKenzie
Collaboration
Argenx Makes $1.5B+ Play for UNP’s Macrocyclic Peptides Aimed at ‘Undruggable’ Targets
July 1, 2025
·
2 min read
·
Tristan Manalac
Mergers & acquisitions
AbbVie Plunks Down $2.1B for Capstan and Its Novel CAR T Therapies
June 30, 2025
·
2 min read
·
Dan Samorodnitsky
